Merck & Co. stock gains two pipeline catalysts ahead of data week
Published on 11/07/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline milestones set up next week
- Merck began the global ENHANCE-3 Phase 3 study of OHTUVAYRE in COPD patients receiving standard care.
- New HIV treatment and prevention data are scheduled for HIV Drug Therapy Glasgow from November 8 to 11.
- The FDA set April 22, 2027, as the target action date for two supplemental IDVYNSO applications.
Merck & Co. added two pipeline catalysts during the week ended Friday, November 6. The company began a global Phase 3 COPD study for OHTUVAYRE and set out new HIV treatment and prevention data for a conference starting next week.
New COPD trial broadens catalyst
Merck announced on November 3 that recruitment had begun for ENHANCE-3, a randomized Phase 3 study evaluating OHTUVAYRE, or ensifentrine, to prevent moderate or severe COPD exacerbations. According to the Merck announcement, the study plans to enroll 2,136 patients in 28 countries, with the first participants enrolling in the United States.
The primary endpoint is the annualized rate of adjudicated moderate or severe COPD exacerbations over 52 weeks. The trial adds a late-stage test to OHTUVAYRE's commercial opportunity, but it does not yet provide efficacy results.
HIV data move into focus
On November 2, Merck said it would present new data from its HIV treatment and prevention portfolio at HIV Drug Therapy Glasgow 2026 from November 8 to 11. The program includes Phase 3 analyses for IDVYNSO, investigational weekly oral regimens and the monthly prevention candidate alimatravir.
The Merck release also said the FDA had accepted two supplemental applications for IDVYNSO, with an April 22, 2027, target action date. The conference therefore offers investors another near-term readout on Merck's efforts to diversify its pipeline.
Merck & Co. stock traded at 131.94 euros on Lang & Schwarz at 11:05 CET on Saturday, November 7, 2026, 0.09 percent above the Xetra close of Friday, November 6, 2026. Investors can follow the real-time quote of Merck & Co. stock.
Merck & Co. stock at a glance
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Home exchange: NYSE
- Lang & Schwarz quote: 131.94 euros on November 7, 2026, at 11:05 CET
- Xetra close: 131.82 euros on November 6, 2026
- Sector: Pharmaceuticals
The S&P 500 remains the relevant US market backdrop for Merck & Co. stock; current market coverage is available here.
More news and analyses on Merck & Co. stock will track the upcoming HIV presentations and further clinical milestones.
